USE OF CHEMOTHERAPY PLUS A MONOCLONAL ANTIBODY AGAINST HER2 FOR METASTATIC BREAST CANCER THAT OVEREXPRESSES HER2
作者： J Ose B Aselga , L Arry N Orton , B Rian L Eyland , W Olfgang E Iermann , D Ennis J. S Lamon
DOI:
关键词:
摘要:
sasse.com 参考文章(31)
M D Pegram, R J Pietras, S B Howell, V R Chazin, B M Fendly, D J Slamon, Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene. ,vol. 9, pp. 1829- 1838 ,(1994)
Richard J. Pietras, David Gallardo, P. Nancy Wongvipat, H. Julie Lee, Joseph C. Poen, Dennis J. Slamon, Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Research. ,vol. 59, pp. 1347- 1355 ,(1999)
Daniel D Von Hoff, Maxwell W Layard, Peter Basa, HUGH L DAVIS Jr, Ann L Von Hoff, Marcel Rozencweig, Franco M Muggia, Risk Factors for Doxorubicin-lnduced Congestive Heart Failure Annals of Internal Medicine. ,vol. 91, pp. 710- 717 ,(1979) , 10.7326/0003-4819-91-5-710
R M Hudziak, G D Lewis, M Winget, B M Fendly, H M Shepard, A Ullrich, p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Molecular and Cellular Biology. ,vol. 9, pp. 1165- 1172 ,(1989) , 10.1128/MCB.9.3.1165
Joan Albanell, Larry Norton, Jose Baselga, Young Mee Kim, John Mendelsohn, Recombinant Humanized anti-HER2 Antibody (Herceptin) Enhances the Antitumor Activity of Paclitaxel and Doxorubicin Against HER2/neu Overexpressing Human Breast Cancer Xenografts Cancer Research. ,vol. 58, pp. 2825- 2831 ,(1998)
R. M. Hudziak, J. Schlessinger, A. Ullrich, Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells Proceedings of the National Academy of Sciences of the United States of America. ,vol. 84, pp. 7159- 7163 ,(1987) , 10.1073/PNAS.84.20.7159
RP A'Hern, IE Smith, SR Ebbs, Chemotherapy and survival in advanced breast cancer : the inclusion of doxorubicin in Cooper type regimens British Journal of Cancer. ,vol. 67, pp. 801- 805 ,(1993) , 10.1038/BJC.1993.146
C. T. Guy, M. A. Webster, M. Schaller, T. J. Parsons, R. D. Cardiff, W. J. Muller, Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease Proceedings of the National Academy of Sciences of the United States of America. ,vol. 89, pp. 10578- 10582 ,(1992) , 10.1073/PNAS.89.22.10578
Gary C. Chamness, Peter M. Ravdin, The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers-A review Gene. ,vol. 159, pp. 19- 27 ,(1995) , 10.1016/0378-1119(94)00866-Q
P. Di Fiore, J. Pierce, M. Kraus, O Segatto, C. King, S. Aaronson, erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells Science. ,vol. 237, pp. 178- 182 ,(1987) , 10.1126/SCIENCE.2885917